 NEW YORK, Nov. 30, 2020 GLOBE NEWSWIRE -- Prevail Therapeutics Inc. Nasdaq: PRVL, a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the European Commission has granted orphan designation for PR006 for the treatment of frontotemporal dementia FTD. PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations FTD-GRN. 